Brought to you by 
Galen acquires Pfizer products
07 Dec 2022
Executive Summary
Galen (women's health, urology, and analgesics) has agreed to acquire Pfizer's oral contraceptives Estrostep and Loestrin and hormone replacement product femhrt for £228.1mm ($359mm) in cash, plus up to £79.4mm ($125mm) more if market exclusivity is sustained for two of those products. If all payments are made, the deal provides Pfizer with 2.3 times the portfolio's 2002 sales.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galen acquires Pfizer products
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice